ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
20 Diciembre 2023 - 7:31AM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health-solutions company, today announced that it has engaged Maxim
Group LLC, to act as the Company’s exclusive financial advisor to
identify potential strategic merger and acquisition partnership
alternatives. The Company does not have a defined timeline for such
a transaction and cannot provide any assurance whether or when any
transaction will be announced or consummated.
About Maxim Group LLCFounded in
2002, Maxim Group is a leading full-service investment bank,
securities and wealth management firm headquartered in mid-town
Manhattan providing a comprehensive array of financial services
including investment banking, global institutional sales, equity
research, fixed income and derivative sales & trading, merchant
capital, private wealth management, and prime brokerage services to
a diverse range of corporate clients, institutional investors and
high-net-worth individuals. Maxim Group is a registered
broker-dealer with the U.S. Securities and Exchange Commission and
the Municipal Securities Rulemaking Board (MSRB). To learn more
about Maxim Group, visit www.maximgrp.com.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
System provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. The
investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system
utilizes a proprietary vagus nerve block and stimulation technology
platform for the treatment of type 2 diabetes and metabolic
disorders. The Obalon® balloon technology is a non-surgical,
swallowable, gas-filled intra-gastric balloon that is designed to
provide long-lasting weight loss. For more information, please
visit www.reshapelifesciences.com.
CONTACTSReShape Lifesciences
Contact:Paul F. HickeyPresident and Chief Executive
Officer949-276-7223ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ReShape Lifesciences (NASDAQ:RSLS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024